Surprising source of serotonin could affect antidepressant activity

Serotonin is a chemical in the brain that plays a key role in regulating various emotions and behaviors. Like other neurotransmitters, which relay signals between neurons, serotonin is stored in small sacs called vesicles in the presynaptic terminal of one neuron and released into the synapse in response to neuronal firing to bind to receptors on a postsynaptic neuron. An imbalance in serotonin signaling is generally thought to contribute to depression.

Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that increase levels of extracellular serotonin by preventing its reuptake by neurons. However, one of the main drawbacks of SSRIs is their delayed effect. A contributing factor to the delay is thought to be that the firing of serotonergic neurons is itself suppressed by extracellular serotonin, which acts on inhibitory neuronal "autoreceptors" in a process known as autoinhibition. Thus, SSRIs -- which are intended to enhance serotonin signaling -- may actually initially slow the therapeutic process.

Now, Boris Mlinar and colleagues from the University of Florence show that, remarkably, the serotonin that mediates autoinhibition appears to be released into the extracellular space through a distinct process. Rather than being released from vesicles in response to neuronal firing (in a process known as exocytosis), the study indicates that this pool of serotonin may be supplied by simple diffusion across the cell membrane. Mlinar and colleagues believe that a full understanding of this process might inform better strategies of modulating serotonin signaling in order to treat depression.